How Scientists Are Treating Breast Cancer Using the Immune System
As a pharmacist, Kathy James considers herself well educated about the importance of getting regular cancer screenings. Even though the 55-year-old had no history of cancer in her family, she never skipped her regular mammograms, and she gave herself regular breast exams. So she was dumbfounded when, during one of those self-exams in May 2017, she felt a marble-size lump in her left breast. A visit to the doctor confirmed it. “The radiologist came in with his hands in his pockets and looked down and said, ‘It doesn’t look good,'” James says. After a biopsy, James and her husband learned she had metastatic breast cancer. It was their 26th wedding anniversary. James immediately wanted to have both breasts surgically removed, which she believed would drastically reduce the chance that the cancer would spread. “I wanted to be done with it all,” she says. “I was hell-bent on getting the double mastectomy.” If James had been diagnosed even five years earlier, she likely would have gone through with the radical surgery, even though it would not have guaranteed her cancer would not spread, or return. A friend who is a cancer doctor advised her against getting the surgery and referred her to Dr. Brian Czerniecki at Moffitt Cancer Center, who told her about a pioneering study he was conducting to test a completely new way of fighting breast cancer–not solely with chemotherapy, radiation or surgery but by harnessing the power of her...
Conclusion: Results concerning muscle dysfunction in smokers are divergent, since some studies have shown worse results in a variety of muscle strength variables in smokers compared with nonsmoking controls, whereas other studies have not. Moreover, there is rather preliminary evidence indicating worse muscle dysfunction and lower CSA in patients with mild COPD in comparison with healthy (or non-COPD) smokers.
UCLA has received a $10 million gift fromThe Eli and Edythe Broad Foundation to fund education, faculty recruitment and retention, and innovative research at the campus ’s stem cell research center. The foundation also announced $10 million gifts to the Broad family’s namesake stem cell research centers UC San Francisco and the University of Southern California, bringing its total support of stem cell research centers in California to $110 million since 2005. “We are proud to support California’s growing stem cell research and treatment infrastructure led by the talented sci...
Combining ultrasound techniques on transrectal ultrasound (TRUS) better identifies...Read more on AuntMinnie.comRelated Reading: AIUM: TRUS or MRI for prostate diagnosis? Prostate cancer incidence, mortality decline worldwide Faster MRI protocol avoids unneeded prostate biopsies MRI-based risk model improves prostate cancer detection MR/TRUS fusion biopsy targets high-risk prostate cancer
Smoking tobacco takes a heavy toll on the immune system --a toll that can be...Read more on AuntMinnie.comRelated Reading: SNMMI: PET spotlights link between Down syndrome, Alzheimer's SNMMI: PET ligand can diagnose brain disorder before autopsy SNMMI: Technetium radiotracer tracks rheumatoid arthritis SNMMI: FDG-PET/MRI improves pain diagnosis, management SNMMI: PSMA-PET helps guide prostate cancer therapy
Researchers from the U.K. used an augmented reality (AR) headset to examine...Read more on AuntMinnie.comRelated Reading: AR headsets speed transition from 2D to 3D in liver imaging AR, 3D printing enhance planning for complex heart surgery AR, 3D printing aid presurgical planning for kidney cancer 4 practical applications of VR, AR in radiology VR, AR elevate radiologists' value in future of medicine
Malignant chondroid syringoma (MCS; malignant mixed tumour) is a rare neoplasm typically arising on the extremities and trunk. We are report 2 unique cases of MCS, one occurring on the scalp of a 78-year-old man and the other on the trunk of a 72-year-old woman. Both tumours harboured malignant epithelial and malignant mesenchymal components. The latter was represented by liposarcoma in the first case. The malignant components of the second tumour comprised spindle cell squamous cell carcinoma (SCC) and osteosarcoma. Origin from a pre-existing benign chondroid syringoma was clearly evident in both neoplasms. The presence o...
Conclusions: In conjunctival melanoma, nuclear localization and activation of β-catenin appear to be limited, suggesting that inhibition of ARF6, responsible for β-catenin activation, in subsets of skin melanoma may not represent a treatment option for this tumor. In vitro, Wnt3a or Wnt5a did not induce nuclear β-catenin localization.Dermatopathology 2019;6:50 –62
CONCLUSION: The final model was demonstrated as appropriate and effective for assessing the pharmacokinetic parameters of delayed MTX excretion in children with ALL. . PMID: 31232278 [PubMed - as supplied by publisher]
More News: Allergy & Immunology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Chemotherapy | Children | Clinical Trials | Colon Cancer | Colorectal Cancer | Databases & Libraries | Environmental Health | Food and Drug Administration (FDA) | Genetics | Guinea Health | Health | HER2 | Hormones | Immunotherapy | Infectious Diseases | Influenza | Influenza Vaccine | Learning | Leukemia | Liver | Lung Cancer | Lymphoma | Mammography | Mastectomy | Measles | Measles Vaccine | Melanoma | Nanotechnology | Physiology | Radiology | Science | Skin | Skin Biopsy | Skin Cancer | Study | Training | Tuberculosis | Universities & Medical Training | University of Pennsylvania | Urology & Nephrology | Vaccines